Loring Wolcott & Coolidge Fiduciary Advisors’s Boston Scientific BSX Stock Holding History

Loring Wolcott & Coolidge Fiduciary Advisors’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$52.6K	Hold	1,233	–	–	﹤0.01%	432
2026 Q1	$76.2K	Hold	1,233	–	–	﹤0.01%	401
2025 Q4	$115K	Sell	1,233 -8,375	-87%	-$821K	﹤0.01%	363
2025 Q3	$984K	Buy	9,608 +8,375	+679%	+$867K	0.01%	167
2025 Q2	$132K	Hold	1,233	–	–	﹤0.01%	321
2025 Q1	$122K	Hold	1,233	–	–	﹤0.01%	313
2024 Q4	$126K	Sell	1,233 -119	-9%	-$10.5K	﹤0.01%	326
2024 Q3	$115K	Buy	1,352 +119	+10%	+$9.38K	﹤0.01%	328
2024 Q2	$96.3K	Hold	1,233	–	–	﹤0.01%	339
2024 Q1	$83.9K	Hold	1,233	–	–	﹤0.01%	350
2023 Q4	$78K	Sell	1,233 -71	-5%	-$3.79K	﹤0.01%	369
2023 Q3	$68.5K	Hold	1,304	–	–	﹤0.01%	394
2023 Q2	$70.5K	Buy	1,304 +71	+6%	+$3.71K	﹤0.01%	401
2023 Q1	$61.7K	Hold	1,233	–	–	﹤0.01%	385
2022 Q4	$57.1K	Hold	1,233	–	–	﹤0.01%	388
2022 Q3	$48K	Hold	1,233	–	–	﹤0.01%	414
2022 Q2	$46K	Hold	1,233	–	–	﹤0.01%	436
2022 Q1	$55K	Hold	1,233	–	–	﹤0.01%	432
2021 Q4	$52K	Hold	1,233	–	–	﹤0.01%	459
2021 Q3	$54K	Sell	1,233 -66	-5%	-$2.92K	﹤0.01%	454
2021 Q2	$56K	Buy	+1,299	New	+$54.6K	﹤0.01%	461
2021 Q1	–	Sell	-1,233	Closed	-$44K	–	360
2020 Q4	$44K	Hold	1,233	–	–	﹤0.01%	440
2020 Q3	$47K	Sell	1,233 -6,890	-85%	-$266K	﹤0.01%	403
2020 Q2	$285K	Sell	8,123 -2,009	-20%	-$72.3K	﹤0.01%	221
2020 Q1	$331K	Buy	10,132 +29	+0.3%	+$1.13K	0.01%	203
2019 Q4	$457K	Hold	10,103	–	–	0.01%	213
2019 Q3	$411K	Hold	10,103	–	–	0.01%	211
2019 Q2	$434K	Hold	10,103	–	–	0.01%	206
2019 Q1	$388K	Hold	10,103	–	–	0.01%	208
2018 Q4	$357K	Hold	10,103	–	–	0.01%	215
2018 Q3	$389K	Hold	10,103	–	–	0.01%	217
2018 Q2	$330K	Hold	10,103	–	–	0.01%	231
2018 Q1	$276K	Hold	10,103	–	–	0.01%	242
2017 Q4	$250K	Sell	10,103 -2,210	-18%	-$61K	﹤0.01%	253
2017 Q3	$359K	Hold	12,313	–	–	0.01%	222
2017 Q2	$328K	Hold	12,313	–	–	0.01%	221
2017 Q1	$306K	Hold	12,313	–	–	0.01%	229
2016 Q4	$266K	Hold	12,313	–	–	0.01%	241
2016 Q3	$293K	Hold	12,313	–	–	0.01%	228
2016 Q2	$288K	Hold	12,313	–	–	0.01%	232
2016 Q1	$232K	Hold	12,313	–	–	0.01%	234
2015 Q4	$227K	Sell	12,313 -1,120	-8%	-$20.1K	0.01%	256
2015 Q3	$238K	Hold	13,433	–	–	0.01%	254
2015 Q2	$238K	Hold	13,433	–	–	0.01%	254
2015 Q1	$238K	Hold	13,433	–	–	0.01%	264
2014 Q4	$178K	Buy	13,433 +775	+6%	+$9.91K	﹤0.01%	293
2014 Q3	$149K	Hold	12,658	–	–	﹤0.01%	302
2014 Q2	$162K	Buy	12,658 +750	+6%	+$9.75K	﹤0.01%	297
2014 Q1	$161K	Hold	11,908	–	–	﹤0.01%	283
2013 Q4	$143K	Hold	11,908	–	–	﹤0.01%	290
2013 Q3	$140K	Hold	11,908	–	–	﹤0.01%	274
2013 Q2	$110K	Buy	+11,908	New	+$101K	﹤0.01%	314

Other funds holding BSX

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $180B AUM 37.51% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

ATO

Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors's BSX Position: Q2 2026 in Review

Loring Wolcott & Coolidge Fiduciary Advisors held its Boston Scientific (BSX) position steady in Q2 2026 at 1,233 shares worth $52.6K. The position accounts for ﹤0.01% of the portfolio, ranked #432.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in BSX in Q2 2013 and has held it in 52 quarters since. The position peaked at $984K in Q3 2025. 720 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

Loring Wolcott & Coolidge Fiduciary Advisors held 1,233 shares of Boston Scientific worth $52.6K as of Q2 2026.
Loring Wolcott & Coolidge Fiduciary Advisors left its Boston Scientific share count unchanged in Q2 2026.
Boston Scientific made up ﹤0.01% of Loring Wolcott & Coolidge Fiduciary Advisors's portfolio in Q2 2026, its #432 holding.
Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Boston Scientific in Q2 2013 and has held it in 52 quarters since.
Loring Wolcott & Coolidge Fiduciary Advisors's Boston Scientific position peaked at $984K in Q3 2025.
720 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.